Myelodysplastic Syndromes – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of myelodysplastic syndromes (MDS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of MDS for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.

Clarivate Epidemiology’s MDS forecast will answer the following questions:

  • In developing countries, what impact will economic growth and development have on the number of people diagnosed with MDS per year?
  • How will improvements in survival change the number of people living with a diagnosis of MDS?
  • Of all people diagnosed with MDS, how many in each country in the developed world are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of MDS over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

Clarivate Epidemiology provides at least 10 years of forecast data for the following MDS patient populations:

  • Diagnosed incident cases of MDS.
  • Diagnosed prevalent cases of MDS.
  • Diagnosed incident cases of MDS by FLT3 status.
  • Diagnosed incident cases of MDS by histology.
  • Diagnosed prevalent cases of MDS by IPSS risk.
  • Diagnosed prevalent cases of MDS by IPSS-R risk.
  • Diagnosed prevalent cases of MDS by histology.
  • Diagnosed incident cases of MDS by FLT3-mutation status.
  • Drug-treated population(s).
  • Diagnosed incident cases of MDS by TP53-mutation status.

… and more (details available on request).

Note: Coverage may vary by country and region.